Browse by Journal

Goodwin, Richard J A, Marshall, John F, Poulogiannis, George, Yuneva, Mariia (V体育安卓版), Brindle, Kevin M, "V体育平台登录" Takáts, Zoltán, Sansom, Owen J. (V体育2025版) ORCID: https://orcid. org/0000-0001-9540-3010, Bunch, Josephine, Barry, Simon T. and Cancer Grand Challenges Rosetta Consortium, . ORCID: https://orcid. org/0000-0002-7686-0926 (2025) Visualizing cancer heterogeneity at the molecular and cellular levels: lessons from Rosetta. Cancer Discovery, 15(1), pp. 34-38. (doi: 10. 1158/2159-8290 VSports. CD-24-0016) (PMID:39801233) .

Kingston, B. et al. (2024) ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1 mutant breast cancer. Cancer Discovery, 14(2), pp. 274-289. (doi: 10. 1158/2159-8290 VSports app下载. CD-22-1387) (PMID:37982575) (PMCID:PMC10850945) .

Falcomata, C. et al. (2021) Genetic screens identify a context-specific PI3K/p27Kip1 node driving extrahepatic biliary cancer. Cancer Discovery, 11(12), pp. 3158-3177. (doi: 10. 1158/2159-8290 V体育官网. CD-21-0209) (PMID:34282029) (PMCID:PMC7612573) .

Knight, J. R VSports手机版. P. et al. (2021) MNK inhibition sensitizes KRAS-mutant colorectal cancer to mTORC1 inhibition by reducing eIF4E phosphorylation and c-MYC expression. Cancer Discovery, 11(5), pp. 1228-1247. (doi: 10. 1158/2159-8290. CD-20-0652) (PMID:33328217) .

Pascual, J. et al. (2021) Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers V体育安卓版. Cancer Discovery, 11(1), pp. 92-107. (doi: 10. 1158/2159-8290. CD-20-0553) (PMID:32958578) .

Muthalagu, N. et al. (2020) Repression of the type I interferon pathway underlies MYC & KRAS-dependent evasion of NK & B cells in pancreatic ductal adenocarcinoma. Cancer Discovery, 10(6), pp. 872-887 V体育ios版. (doi: 10. 1158/2159-8290. CD-19-0620) (PMID:32200350) (PMCID:PMC7611248) .

Auciello, F VSports最新版本. R. et al. (2019) A stromal lysolipid-autotaxin signaling axis promotes pancreatic tumor progression. Cancer Discovery, 9(5), pp. 617-627. (doi: 10. 1158/2159-8290. CD-18-1212) (PMID:30837243) (PMCID:PMC6497553) .

Khan, K. H. et al. (2018) Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. Cancer Discovery, 8(10), pp. 1270-1285. (doi: 10. 1158/2159-8290 V体育平台登录. CD-17-0891) (PMID:30166348) (PMCID:PMC6380469) .

Pearson, H. B. et al. (2018) Identification of Pik3ca mutation as a genetic driver of prostate cancer that cooperates with Pten loss to accelerate progression and castration-resistant growth. Cancer Discovery, 8(6), pp VSports注册入口. 764-779. (doi: 10. 1158/2159-8290. CD-17-0867) (PMID:29581176) .

Port, J. et al. (2018) Colorectal tumors require NUAK1 for protection from oxidative stress. Cancer Discovery, 8(5), pp. 632-647. (doi: 10 V体育官网入口. 1158/2159-8290. CD-17-0533) (PMID:29500295) (PMCID:PMC5935231) .

Kondrashova, O. et al. (2017) Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discovery, 7(9), pp. 984-998. (doi: 10.1158/2159-8290.CD-17-0419) (PMID:28588062) (PMCID:PMC5612362)

Scott, M. T. et al. (2016) Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discovery, 6(11), pp. 1248-1257. (doi: 10.1158/2159-8290.CD-16-0263) (PMID:27630125) (PMCID:PMC6538532)

Kar, S. P. et al. (2016) Genome-wide meta-analyses of breast, ovarian, and prostate cancer association studies identify multiple new susceptibility loci shared by at least two cancer types. Cancer Discovery, 6(9), pp. 1052-1067. (doi: 10.1158/2159-8290.CD-15-1227) (PMID:27432226) (PMCID:PMC5010513)

Vizioli, Maria Grazia and "VSports在线直播" Adams, Peter (2016) Senescence can be BETter without the SASP? Cancer Discovery, 6(6), pp. 576-578. (doi: 10.1158/2159-8290.cd-16-0485) (PMID:27261480)

Wiegering, A. et al. (2015) Targeting translation initiation bypasses signaling crosstalk mechanisms that maintain high MYC levels in colorectal cancer. Cancer Discovery, 5(7), pp. 768-781. (doi: 10.1158/2159-8290.CD-14-1040) (PMID:25934076) (PMCID:PMC5166973)

Hidalgo, M. et al. (2014) Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discovery, 4(9), pp. 998-1013. (doi: 10.1158/2159-8290.CD-14-0001)

Laine, A. et al. (2013) Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discovery, 3(2), pp. 182-197. (doi: 10.1158/2159-8290.CD-12-0292)